Back to Search
Start Over
Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
- Source :
-
Open Forum Infectious Diseases . Fall2015, Vol. 2 Issue 4, p1-4. 4p. - Publication Year :
- 2015
-
Abstract
- Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect was neuropathy. We propose that LNZ should be reclassified among bactericidal second-line drugs. [ABSTRACT FROM AUTHOR]
- Subjects :
- *LINEZOLID
*MULTIDRUG resistance
*TUBERCULOSIS treatment
Subjects
Details
- Language :
- English
- ISSN :
- 23288957
- Volume :
- 2
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Open Forum Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 112080610
- Full Text :
- https://doi.org/10.1093/ofid/ofv175